Citius Pharmaceuticals, Inc. (CTXR) News

Citius Pharmaceuticals, Inc. (CTXR): $0.65

0.02 (-2.86%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add CTXR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#354 of 362

in industry

Filter CTXR News Items

CTXR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CTXR News From Around the Web

Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity.

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | December 3, 2023

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November ...

Yahoo | November 14, 2023

Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on November 15, 2023.

Yahoo | November 9, 2023

Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that preclinical research on LYMPHIR ("denileukin diftitox" or "E7777") was published today in Frontiers in Immunology1, a leading peer-reviewed journal in the immunology field. The article reported positive results from a preclinical study that showed that denileukin diftitox in combination with an anti-PD-1 checkpoint inhibitor was more effective in the treatment of solid tumors (liver and colon) than eithe

Yahoo | October 31, 2023

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition ("TenX") (NASDAQ: TENKU), a publicly traded special purpose acquisition company (SPAC), today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma's wholly owned oncology subsidiary that will continue as a public c

Yahoo | October 24, 2023

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from over 30 of the most innovative companies at the forefront of healthcare, technology and consu

Yahoo | September 21, 2023

Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, has rescheduled its participation in Sidoti's Small-Cap Virtual Conference to November 2023 due to funeral services for the late Howard Safir, a long-time member of the Citius Board. Mr. Mazur was originally scheduled to present at the Sidoti Small-Cap Virtual Conference on Wednesday, September

Yahoo | September 18, 2023

Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) mourns the loss of longtime board member, Howard Safir, who passed away on Monday. Mr. Safir joined the Citius Board of Directors in 2014, providing invaluable counsel to the Citius management team for nearly a decade.

Yahoo | September 13, 2023

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) is pleased to announce the Company has received additional guidance from the U.S. Food and Drug Administration (FDA) regarding the planned resubmission of the Company's Biologics License Application (BLA) for LYMPHIR™ (denileukin diftitox), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

Yahoo | September 8, 2023

Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two investor conferences in September 2023. Citius Chairman and CEO Leonard Mazur will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, and at the Sidoti Small-Cap Virtual Conference on Wednesday, Septemb

Yahoo | September 6, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!